Clinical Trial Search

Primary: Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria — 70.4 percentage…

Primary: Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) — 1 Participants

Primary: Hemoglobin Levels at 12-weeks. Marginal Means (95% CI). — 123; 116; 121; 116 g/L — p=<0.05

Primary: Immune Response — 7 Particpants

Primary: Progression-Free Survival (PFS) — 7.63; 6.83 Months — p== 0.0100

Primary: Number of Participants With Serious and Non-serious Adverse Events — 45 Participants

Primary: Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE) — 1.55; 0.80; 0.46; 0.89 units on a scale * year

Primary: Percentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <20 International Unit Per Milliliter (IU/mL) at Week 144 — 77.0 Percentage of…

Primary: 2 Year Progression Free Percent — 62.5 percentage of participants

Primary: Maximum Safinamide Plasma Concentration (Cmax) — 411.5; 792.1; 465.0; 825.3 nanogram/milliliter (ng/mL)

Primary: Phase I: Number of Patients With Dose Limiting Toxicity — 0; 0; 0; 0 Participants

Primary: Overall Response Rate (ORR) - Percentage of Participants With Partial Response or Better With Induction Regimen — 77.2 percentage of participants

Primary: Number of Participants That Had Any Grade ≤2, and 3, 4 and 5 Adverse Events Following Administration of T Cells Expressing Anti- Signaling Lymphocytic Activation…

Primary: Continuous Glucose Monitoring - Time in Range (70-140 mg/dl) — 36.3; 45.6; 37.2; 43.9 percentage of Time in Range 70-140mg/dL — p=<0.05

Primary: Change in the Number of Enhancing Leptomeningeal Foci on 1 Year Follow up Compared to Baseline in MS Patients Treated With Ocrelizumab. — 0.07 number of enhancing foci